Making Reimbursement Work In a Post-Healthcare Reform World

dollarThe passage of healthcare reform in March brought a wave of reimbursement-related headaches to the life science industry. The pharmaceutical industry will have to dole out $80 billion in discounts over the next 10 years, while a 2.3% excise tax levied on medical device sales has created consternation among device makers. With these developments, many industry innovators are understandably concerned over how healthcare reform will impact reimbursement for their products. How can an emerging pharmaceutical or medical device company maximize its reimbursement in today’s confusing healthcare landscape?

Attendees of the OneMedForum New York 2010 conference, held June 29-30, will have the opportunity to learn more about this complex subject at a “Reimbursement Workshop.” With healthcare reform underway, it will be imperative for companies to be more aggressive in developing robust reimbursement plans and consider evidence development much earlier in the planning cycle. The Reimbursement Workshop will cover many facets of the reimbursement process, including the importance of including reimbursement early in strategic planning to avoid costly and time-consuming errors. Attendees will learn how healthcare reform may impact their business, how to avoid common mistakes, how to improve valuation with a pricing strategy that connects the clinical or economic value of the technology, and more.  The workshop will be held by Patty Telgener, Director of Pricing and Reimbursement at Gershon Capital & Cie.

The Reimbursement Workshop”  scheduled for Wednesday, June 30, 2010 from 9:50-10:35 a.m. Additional information about this and other workshops at the OneMedForum New York 2010 can be found at

For more information on the conference, including a list of presenting companies, visit

The comments are closed.